实例探究 > MorphoSys Accelerates Antibody R&D with Genedata Biologics

MorphoSys Accelerates Antibody R&D with Genedata Biologics

公司规模

1,000+

地区

Europe

国家

Germany

产品

Genedata Biologics

技术栈

Data Management Platform
Workflow Platform

实施规模

Enterprise-wide Deployment

影响指标

Cost Savings
Productivity Improvements

技术

平台即服务 (PaaS) - 数据管理平台

适用行业

生命科学
药品

适用功能

产品研发

用例

质量预测分析

服务

数据科学服务

关于客户

MorphoSys is a late-stage biopharmaceutical company devoted to the development of innovative and differentiated therapies for patients suffering from serious diseases. Based on its proprietary technology platforms and leadership in the field of therapeutic antibodies, MorphoSys, together with its partners, has participated in the development of more than 100 therapeutic product candidates currently in R&D. The company has one of the broadest pipelines in the biotechnology industry, including unique approaches for patients with conditions such as cancer, Alzheimer’s disease, infectious diseases, cardiovascular dysfunction, and inflammation. The MorphoSys pipeline is based on a combination of strong business partnerships and proprietary development activities. MorphoSys has partnered with major biopharmaceutical companies including Astellas, Bayer, Merck & Co., Boehringer Ingelheim, Novartis, Janssen, Pfizer, Daiichi Sankyo, F. Hoffmann-La Roche, and Shionogi. Using MorphoSys’ proprietary synthetic antibody libraries and their phage display screening technologies HuCAL, Ylanthia, and Slonomics, MorphoSys enables faster, more flexible and, ultimately, better-quality access to drug candidates.

登录后查看完整内容

挑战

MorphoSys, a late-stage biopharmaceutical company, was facing challenges due to its rapid growth. The increase in molecule and sample throughput led to a significant amount of R&D data, which was difficult to capture, process, and interpret. The scale and throughput of their operations necessitated the use of an enterprise workflow platform to manage and streamline the growing number of their discovery programs. The goal of the new system was to make MorphoSys’ sophisticated R&D processes more efficient and to facilitate handovers between various R&D teams and functions, including screening, molecular biology, engineering, expression, purification, and analytics. The new system also needed to be able to handle the increasing amount of data and samples produced by external partners, such as CROs, which had to be integrated into MorphoSys’ R&D process.

登录后查看完整内容

解决方案

After a formal selection process, MorphoSys decided to implement Genedata Biologics as their new enterprise workflow platform, which they internally refer to as “Ybase”. A key reason for this decision was the fact that Genedata Biologics is the only turnkey system available in the antibody R&D space. This allowed for rapid deployment and gave MorphoSys full process coverage right from the start. Genedata Biologics was deployed as MorphoSys’ end-to-end workflow platform across all discovery and development units. As part of the deployment project, the platform was integrated with all relevant laboratory equipment and IT systems, ensuring smooth and efficient data exchange between different systems and groups. Today, Genedata Biologics is MorphoSys’ enterprise workflow system for 150 users, including scientists, program managers, engineers, technicians, IT, and management. In addition, the system has become the central “mission-control center” for all their partnered and proprietary development programs.

登录后查看完整内容

运营影响

Using Genedata Biologics as their central workflow platform, the MorphoSys R&D teams can now access all project information in real time. The ability to immediately see the status of any project at any time allows for more informed and rapid decision-making at all levels – from corporate leaders to scientists, engineers, and technical staff.
This access to R&D information has transformed how MorphoSys operates today. In dedicated project dashboards, all teams can look up project information such as molecule characteristics (e.g., sequences, assay data, analytics data), as well as operational key performance indicators (KPIs) that help them more effectively make decisions.
Using a shared workflow platform also encourages all collaborators to review, comment on, and use the same data and planning information. This improves accuracy and quality of critical project data, and effectively cuts down on redundancies and inconsistencies.
As an additional plus, teams no longer need to create manual reports, as reporting is now the result of day-to-day operations. After each step in the R&D workflow, such as for an antibody optimization campaign, the responsible scientists register all relevant data (e.g., binding, activity data) and the drug candidate information is automatically updated for the next step in the workflow.

登录后查看完整内容

数量效益